2012, Number 2
<< Back Next >>
Med Sur 2012; 19 (2)
Reynaud’s phenomenon secondary to Diffuse Scleroderma
Carrillo-Esper R, Ramírez-Hinojosa JP, Lázaro-Rosales ES
Language: Spanish
References: 11
Page: 111-115
PDF size: 88.71 Kb.
ABSTRACT
Raynaud’s phenomenon (RP) affects 3-5% of the population, which
may be primary or secondary to underlying disease. It is characterized
by sudden transient and recurrent episodes of pallor and/or
digital cyanosis. Connective tissue disease, particularly systemic
sclerosis, is the main causes of the RP. In the RP there is imbalance
between vasoconstricting and vasodilating factors. Physical examination
nailfold capillaroscopy and immunological test can differentiate
primary from secondary RP. Mild RP can be managed with
conservative non-pharmacological lifestyle modifications. In the
severe RP vasodilator treatment is needed. In refractory cases with
critical digital ischemia, intravenous treatment with prostaglandin
analogues and surgery are useful.
REFERENCES
Steen V. The many faces of scleroderma. Rheum Dis Clin N Am 2008; 34: 1-15.
Gayraud M. Raynaud’s phenomenon. Joint Bone Spine 2007; 74: 1-8.
García CM, Jimenez HM, Escárcega R, Mendoza PC, Pardo SR, Galarza MC, et al. Treatment of Raynaud’s phenomenon. Autoimmunity Reviews 2008; 8: 62-8.
Herrick A. Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005; 44: 587-96.
Baumhäkel M, Böhm M. Recent achievements in the management of Raynaud’s phenomenon. Vasc Health Risk Manag 2010; 6: 207-14.
Flavahan A. Regulation of vascular reactivity in scleroderma: New insights into Raynaud’s Phenomenon. Rheum Dis Clin North Am 2008; 34: 81-7.
Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 2006; 45: 43-6.
Huisstede R, Hoogvliet C. Effectiveness of Interventions for Secondary Raynaud’s Phenomenon: a systematic review. Arch Phys Med Rehabil 2011; 92: 32-8.
Thompson A, Pope E. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology 2005; 44: 145-50.
Riemekasten G, Sunderkötter C. Vasoactive therapies in systemic sclerosis. Rheumatology 2006; 45: 49-51.
Kotsis S, Chung K. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003; 30: 1788-92.
Full text